Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Holding TRVI?
Track your performance easily
See the Price Targets and Ratings of:
TRVI Analyst Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TRVI Stock 12 Month Forecast
Average Price Target
$9.11
▲(164.83% Upside)
| Highest Price Target$21.00 | Average Price Target$9.11 | Lowest Price Target$6.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
Initiated
09/09/24
Raymond James
Initiated
08/30/24
H.C. Wainwright
Initiated
08/30/24
EF Hutton
Initiated
08/19/24
Oppenheimer
Reiterated
08/14/24
B.Riley Financial
Reiterated
08/13/24
Stifel Nicolaus
Reiterated
08/09/24
Needham
Reiterated
08/09/24
Rodman & Renshaw
Initiated
06/12/24
―
JonesTrading
―
Buy
―
Reiterated
08/09/24
We are transferring the coverage of Trevi Therapeutics (TRVI), reiterating our Buy rating, with a new PT of $8 (up from $7). Investment . Haduvio has shown early but potent antitussive effects in idiopathic pulmonary fibrosis (IPF). We believe Haduvio is likely to show similar cough benefit at the 2H24 proof-of-concept update in refractory chronic cough (RCC). A positive update in RCC, a large indication, is likely to drive upward momentum in shares vs current levels. Next, while Haduvio falls in the opioid class, its differentiated molecular profile likely limits its human abuse potential (HAP). To that end, favorable data from Haduvio’s HAP study (expected 2H24) could help address any class related overhang. Taken together, the profile of upcoming catalysts appear positively skewed.
Best Analysts Covering Trevi Therapeutics
Which Analyst Should I Follow If I Want to Buy TRVI and Sell After:
1 Month
xxx
Success Rate
5/7 ratings generated profit
Average Return
+2.41%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 71.43% of your transactions generating a profit, with an average return of +2.41% per trade.
3 Months
xxx
Success Rate
4/7 ratings generated profit
Average Return
+29.10%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +29.10% per trade.
1 Year
Success Rate
7/9 ratings generated profit
Average Return
+36.14%
reiterated a buy rating 3 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +36.14% per trade.
2 Years
xxx
Success Rate
8/9 ratings generated profit
Average Return
+45.58%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +45.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TRVI Analyst Recommendation Trends
Rating
May 24
Jun 24
Jul 24
Aug 24
Sep 24
Strong Buy
9
5
5
11
11
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
9
5
5
11
11
Each month's total comprises the sum of three months' worth of ratings.
TRVI Financial Forecast
TRVI Stock Forecast FAQ
What is TRVI’s average 12-month price target, according to analysts?
Based on analyst ratings, Trevi Therapeutics Inc’s 12-month average price target is $9.11.
What is TRVI’s upside potential, based on the analysts’ average price target?
Trevi Therapeutics Inc has 164.83% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TRVI a Buy, Sell or Hold?
Trevi Therapeutics Inc has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
What is Trevi Therapeutics Inc’s price target?
The average price target for Trevi Therapeutics Inc is $9.11. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $21.00 ,the lowest forecast is $6.00. The average price target represents 164.83% Increase from the current price of $3.44.
The highest analyst price target is $21.00 ,the lowest forecast is $6.00. The average price target represents 164.83% Increase from the current price of $3.44.
What do analysts say about Trevi Therapeutics Inc?
Trevi Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of TRVI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.